磺達嗪INN:sulforidazine)是一種典型抗精神病藥硫利達嗪英語Thioridazine代謝產物。它與美索達嗪英語Mesoridazine都比母體化合物更有效,這表明了硫利達嗪的藥理反應可能主要是其代謝產生活性化合物的結果。[1]

磺達嗪
臨床資料
ATC碼
  • 未分配
識別資訊
  • 102-[(RS)-1-Methylpiperidin-2-yl]ethyl2-(methylsulfonyl)-10H-phenothiazine
CAS號14759-06-9  checkY
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.035.274 編輯維基數據鏈接
化學資訊
化學式C21H26N2O2S2
摩爾質量402.57 g·mol−1
3D模型(JSmol英語JSmol
  • O=S(=O)(c2cc1N(c3c(Sc1cc2)cccc3)CCC4N(C)CCCC4)C
  • InChI=1S/C21H26N2O2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)26-21-11-10-17(15-19(21)23)27(2,24)25/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3 checkY
  • Key:FLGCRGJDQJIJAW-UHFFFAOYSA-N checkY

合成

 
Thieme 合成:[2]專利:[3]

參考資料

  1. ^ Niedzwiecki DM, Mailman RB, Cubeddu LX. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors. Journal of Pharmacology and Experimental Therapeutics. March 1984, 228 (3): 636–9. PMID 6707914. 
  2. ^ Morrow, Ryan J.; Millership, Jeff S.; Collier, Paul S. (2005). "Facile Syntheses of the Three Major Metabolites of Thioridazine". Helvetica Chimica Acta. 88 (5): 962–967. doi:10.1002/hlca.200590089.
  3. ^ FR1363683 idem Bruschweiler Conrad, Schwarb Gustav, Winkler Hans, Renz Jany, 美國專利第3,314,948號 (1967 to Sandoz Ltd).